Bionomics Limited (BNOX)
NASDAQ: BNOX · Real-Time Price · USD
0.476
+0.284 (149.26%)
Nov 5, 2024, 3:57 PM EST - Market open
Bionomics Employees
As of June 30, 2024, Bionomics had 24 total employees, including 8 full-time and 16 part-time employees.
Employees
24
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$645,507
Market Cap
8.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| iSpecimen | 53 |
| Petros Pharmaceuticals | 21 |
| Biodexa Pharmaceuticals | 21 |
| InMed Pharmaceuticals | 13 |
| Palisade Bio | 9 |
| Oragenics | 5 |
| Tharimmune | 3 |
| Avenue Therapeutics | 3 |
BNOX News
- 23 hours ago - Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program - GlobeNewsWire
- 13 days ago - Bionomics to Present at the ThinkEquity Conference - GlobeNewsWire
- 22 days ago - Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - GlobeNewsWire
- 5 weeks ago - Bionomics Limited announces intention to re-domicile to the United States - GlobeNewsWire
- 2 months ago - Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - GlobeNewsWire
- 3 months ago - Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 - GlobeNewsWire
- 3 months ago - Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder - GlobeNewsWire